Navigation Links
AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
Date:10/29/2007

CAMBRIDGE, United Kingdom and GAITHERSBURG, Md., Oct. 29 /PRNewswire/ -- Cambridge Antibody Technology (CAT) is changing its name to MedImmune to reflect AstraZeneca's vision for its worldwide biologics business. The new business unit will unite the resources and expertise from CAT, the pre- existing MedImmune and other biologics activities within the AstraZeneca Group, under the "MedImmune" name. With this structure, AstraZeneca has immediately created one of the world's leading vertically integrated biotechnology businesses, with more than $1.3 billion in revenues in 2006, a pipeline of approximately 100 research projects and more than one dozen clinical product candidates, and more than 3,000 employees worldwide.

"The new MedImmune is now the operationally independent and strategically aligned biologics business unit of AstraZeneca," said David M. Mott, MedImmune president and chief executive officer. "Bringing together the biologics expertise of CAT, MedImmune and AstraZeneca allows us to preserve MedImmune's traditional biotech agility and entrepreneurial spirit while encouraging strategic collaboration and cross fertilization of ideas under AstraZeneca's world-class research umbrella."

As part of the integration, John Stageman, Ph.D., vice president of AstraZeneca biopharmaceutical strategic planning, assumes the role of interim site head in Cambridge. Dr. Stageman commented, "AstraZeneca's biologics capabilities have been enhanced significantly by the acquisitions of CAT and MedImmune to create a more robust, highly competitive and fully integrated biotechnology business. The scientific, technical and medical expertise that this team brings together is world class in discovering, developing, manufacturing and commercializing biopharmaceutical products."

AstraZeneca acquired CAT, a biopharmaceutical company committed to developing human monoclonal antibody therapeutics, in June 2006 with the intent to have biologics account for 25-percent of its product pipeline by 2010. In 2007, AstraZeneca accelerated achievement of this biologics strategy through the successful acquisition of MedImmune, a fully integrated biotechnology company and one of the world's ten largest within the industry,

About the New MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. With approximately 3,000 employees worldwide and headquarters in Maryland, MedImmune is dedicated to advancing science and medicine to help people live better lives and is wholly owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune's website at http://www.medimmune.com.


'/>"/>
SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The worldwide growth of ag biotech
2. Midwest holds strong position in worldwide diagnostics business
3. Globalization of biotech industry is a decidedly worldwide phenomenon
4. EraGen cystic fibrosis test to be distributed worldwide through Bayer
5. UW Academic ADL Co-Lab joins worldwide effort against slavery
6. Glacial records depict ice age climate in synch worldwide
7. AIDS and tobacco are worldwide killers: Is bioscience doing enough to stop them?
8. Oskar Anderson to succeed Miszewski as head of state technology division
9. Metavante forms cash-management division
10. Metavante expands healthcare payments division
11. Quintessence division to develop drug tests with NIH grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)...  On January 10 at the Medtech Showcase held ... Conference in San Francisco , ProclaRx ... to pharmaceutical leaders and public and private investors about ... and destroy biofilms.  Biofilms are a ... the body,s immune system from eradicating chronic infections. Infections with ...
(Date:1/16/2017)... , ... January 16, 2017 , ... ... the prestigious Tibbetts Award from the U.S. Small Business Administration. The ... created a significant economic or social impact […] and are considered the best of ...
(Date:1/14/2017)... -- The Alliance for Safe Biologic Medicines (ASBM) today issued ... guidance on biologic naming: We commend ... importance of distinct naming for all biologics, including biosimilars. ... will bring to patients, including new treatment options and ... the Guidance dealing with suffix design remains at odds ...
(Date:1/13/2017)... ... January 13, 2017 , ... Two Kalamazoo entrepreneurs have launched ... acid that farms, greenhouses and hydroponics operations use to increase yields and promote ... growing segments of customers using this high grade fulvic acid extracted from a ...
Breaking Biology Technology:
(Date:1/11/2017)... , Jan. 11, 2017 Intoxalock, a ... with the release of its patent-pending calibration device. With ... reliably perform calibrations, securely upload data logs and process ... the customer. "Fighting drunk driving through the ... the public at large, but also for the customer ...
(Date:1/6/2017)... 2017  Delta ID Inc., a leader in consumer-grade ... automotive at CES® 2017. Delta ID has collaborated with ... the use of iris scanning as a secure, reliable ... in a car, and as a way to elevate ... Delta ID and Gentex will demonstrate (booth #7326 ...
(Date:12/22/2016)... Dec. 20, 2016  As part of its longstanding mission ... personal genetics company, recently released its latest children,s book, titled ... book focuses on the topics of inheritance and variation of ... (NGSS) taught in elementary school classrooms in the US. ... by illustrator Ariana Killoran , whose previous book with ...
Breaking Biology News(10 mins):